The oral LD, of DARANIDE is 1710 and 2600 mg/kg in the mouse and rat respectively.

Symptoms of overdosage or toxicity may include drowsiness, anorexia, nausea, vomiting, dizziness, paresthesias, ataxia, tremor and tinnitus.

In the event of overdosage, induce emesis or perform gastric Lavage. The electrolyte disturbance most likely to be encountered from overdosage is hyperchloremicacidosis that may respond to bicarbonate administration. Potassium supplementation may be required. The patient should be carefully observed and given supportive treatment.

DARANIDE is contraindicated in hepatic insufficiency, renal failure, adrenocortical insufficiency, hyperchloremic acidosis, or in conditions in which serum levels of sodium or potassium are depressed. DARANIDE should not be used in patients with severe pulmonary obstruction who are unable to increase their alveolar ventilation since their acidosis may be increased.

DARANIDE is contraindicated in patients who are hypersensitive to this product.

Bookmark this page: